RxDoctor Payments DataLook up a doctor →

Hassen Borhot, NP

Acute Care · Manchester, CTNPI 1457660029

Payments from drug & device makers

$75,023in general payments, 2019–2025

Across 1,006 payments — averaging $74.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$30K
  • Lilly USA, LLC$24K
  • AbbVie$11K
  • GSK$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$764
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$2,4003%
  • Speaking & faculty fees$42,91557%
  • Travel & lodging$11,12415%
  • Food & beverage$18,56325%
  • Education$200%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,023 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Connecticut.

See all acute care providers in Connecticut

Medicare billing

Part B allowed, 2024
$17,279
Medicare patients
99
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide495$541,168
OzempicSemaglutide216$229,894
FarxigaDapagliflozin Propanediol118$137,753
JardianceEmpagliflozin92$108,467
EliquisApixaban40$41,281
RybelsusSemaglutide17$33,942
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,588
TrulicityDulaglutide20$26,295
JanuviaSitagliptin Phosphate21$21,152
VraylarCariprazine Hcl12$16,772
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,659
Breo ElliptaFluticasone/Vilanterol15$9,829
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,377
Atorvastatin Calcium376$7,116
Repatha SyringeEvolocumab11$6,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$24,136$567,463515 claims
Novo NordiskOzempic, Rybelsus$29,789$263,837233 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,424$149,412131 claims
Boehringer IngelheimJardiance$764$108,46792 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,435$43,79468 claims
PfizerEliquis$631$41,28140 claims
AbbVieVraylar, Synthroid$11,483$18,06726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Connecticut.

Other acute care in Manchester

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →